ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

ODAC Meets at ASCO, Recommends Approval Of Dasatinib For CML.

June 9, 2006

Drug Approvals: FDA Approves Vectibix in mCRC With KRAS Companion Diagnostic

May 30, 2014

Page 2: The Debate Over Brigham’s Containment Bag Study

November 21, 2014

Anti-NCI Forces Fail to Raid $70 Million from Cancer Program

September 26, 1975

AIDS Commission Asks, “Give Us A Chance”

September 18, 1987

CALGB Grant OKed, But Group May Lose Support For Its Non-Hematologic Segments

January 8, 1982